Company intelligence / Profile preview

PrEP Biopharm

Kingston Upon Thames, Greater London, United Kingdomprnewswire.com ↗

Ownership: Private
Employees: ~9
Development stage: Other

Overview

PrEP Biopharm developed a prophylactic nasal spray drug candidate ("PrEP‑001") designed to stimulate the innate immune system via TLR3 and MDA5 receptors in the nasal mucosa. The product showed preclinical efficacy against multiple respiratory viruses including rhinovirus, MERS, and SARS. Phase I and IIa studies demonstrated safety and proof-of-concept for prevention of viral upper respiratory infections. The company completed toxicology studies enabling further field studies but entered liquidation before advancing to later clinical stages[6].

Therapeutic areas: Infectious Diseases
Modalities: Small moleculeNasal powder formulation
Industry: Biotech

Partnerships

No major pharma partnerships disclosed beyond original spinout from Johnson & Johnson.

Beyond the preview

Go deeper on PrEP Biopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PrEP Biopharm.

Explore the full profile